AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aethlon Medical Inc. (AEMD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.65

-0.01 (-2.08%)

At close: Jan 21, 2025, 3:59 PM

0.68

5.11%

After-hours Jan 21, 2025, 07:28 PM EST

undefined% (undefined)

Bid	0.63
Market Cap	9.08M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.79
PE Ratio (ttm)	-0.23
Forward PE	n/a
Analyst	Buy

Ask	0.68
Volume	303,260
Avg. Volume (20D)	3,285,310
Open	0.66
Previous Close	0.66
Day's Range	0.63 - 0.70
52-Week Range	0.24 - 2.10
Beta	undefined

About AEMD

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc....

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Mar 4, 1999

Employees 14

Stock Exchange NASDAQ

Ticker Symbol AEMD

Website https://www.aethlonmedical.com

Analyst Forecast

According to 1 analyst ratings, the average rating for AEMD stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 976.92% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+33.83%

Aethlon Medical shares are trading higher after th... Unlock content with Pro Subscription

2 months ago

+5.98%

Aethlon Medical shares are trading higher after the company announced it enrolled its first patient in its Australian hemopurifier cancer trial targeting patients with solid tumors unresponsive to anti-pd-1 therapy.

News

2 months ago · newsfilecorp.com

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot...

2 months ago · seekingalpha.com

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chi...

2 months ago · newsfilecorp.com

Innovative Medical Technology Advances with First Patient Enrollments

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical te...